TRASTUZUMAB (Herceptin) prior authorization at Regence
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
Regence requires HER2/neu Receptor Antagonist prior-authorization documentation for TRASTUZUMAB (Herceptin): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return on the clock printed in the current member-specific payer source; if denied, use the appeal window printed on the denial notice to appeal.
The PA criteria you'll need to meet
Regence reviews TRASTUZUMAB (Herceptin) prior authorizations against its medical policy for HER2/neu Receptor Antagonist. Regence-specific context: BCBS licensee operating in Oregon, Washington (Clark/Cowlitz counties), Idaho, and Utah (~3.1M members). Subsidiary of Cambia Health Solutions. Prime Therapeutics PBM. Each state's DOI handles complaints for policies issued in that state.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in HER2/neu Receptor Antagonist
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- Regence's medical policy URL referenced in the cover letter
Denial scenarios to check against the current policy
These are preparation scenarios, not frequency claims. Use only those supported by the current member-specific source:
- Cross-state coordination for multi-state members (OR/WA/ID/UT)
- Step therapy via Prime Therapeutics
- Behavioral health network adequacy
- Specialty drug PA
TRASTUZUMAB (Herceptin)-specific review scenarios and context
Check whether the current notice cites any of these label-, REMS-, or policy-related scenarios:
- Plan-mandated biosimilar switch mid-treatment
- HER2 IHC 2+ with FISH equivocal — plan demands IHC 3+
- Adjuvant duration beyond 1 year
- Site-of-care reduction
Brand: Herceptin. Reference biologic for HER2-positive breast and gastric cancer. Biosimilars: Kanjinti, Trazimera, Ogivri, Ontruzant, Herzuma. Also a component of Enhertu (trastuzumab deruxtecan, separate molecule) and Kadcyla.
Manufacturer patient-assistance program: Genentech Patient Foundation — relevant when a Regence denial sticks and the patient needs bridge access while appealing.
How Regence approaches Biosimilars PAs
For TRASTUZUMAB (ONTRUZANT), check whether the current Regence Biosimilars policy cites step therapy via prime therapeutics or specialty drug pa. Pharmacy-benefit review for TRASTUZUMAB (ONTRUZANT) at Regence is routed through Prime Therapeutics. The applicable review clock depends on the member's current product, whether the request is complete and urgent, and governing plan rules. Confirm receipt and timing with Regence; if denied, use the filing date and route printed on that denial notice. Regence treats interchangeability designation and prescriber "dispense-as-written" language as the two pivot points for biosimilar-vs-reference disputes. Regence is domiciled in OR, so unresolved appeals escalate to the OR insurance department's external-review program for fully-insured policies (self-funded ERISA plans route to the DOL EBSA instead).
If the PA is denied
Verify the appeal window and decision clock in the current denial notice and member-specific payer source before relying on either. Submit through the provider portal (https://www.regence.com/provider) with the same packet plus an applicable, current clinical source supporting TRASTUZUMAB (Herceptin)for the patient's indication.
Contact Regence
- Provider portal: https://www.regence.com/provider
Frequently asked questions
What documentation does Regence need for TRASTUZUMAB (Herceptin) prior auth?
Regence's typical PA packet for TRASTUZUMAB (Herceptin): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis. For HER2/neu Receptor Antagonist, expect clinical-criteria documentation specific to this class.
What's the turnaround time at Regence?
Verify the decision clock in the current member-specific payer policy and request receipt. Product type, urgency, state law, and plan terms can change the applicable timing; this page does not supply an operational deadline.
What documentation issues should be checked for TRASTUZUMAB (Herceptin) at Regence?
Preparation scenarios to check against the current notice and policy include: Cross-state coordination for multi-state members (OR/WA/ID/UT); Step therapy via Prime Therapeutics; Behavioral health network adequacy. These are not measured frequency claims. For TRASTUZUMAB (Herceptin), verify whether the actual denial raises step therapy, indication, or another plan-specific criterion before responding.
Can Regence force a mid-treatment switch from the reference biologic to TRASTUZUMAB (ONTRUZANT)?
Regence can require biosimilar use at initiation, but mid-treatment forced switches face higher appeal-reversal rates when the chart documents a stable patient, a defined transition-of-care concern, or prescriber "dispense-as-written" intent supported by a clinical rationale (immunogenicity history, nocebo response in prior switches, narrow therapeutic window). Cite the FDA Purple Book interchangeability designation when arguing the switch — interchangeable biosimilars permit pharmacy substitution; non-interchangeable biosimilars do not. Pharmacy-benefit handling is routed through Prime Therapeutics. External-review escalation for Regence fully-insured policies sits with the OR insurance department.
How do I prep for a peer-to-peer with Regence on TRASTUZUMAB (Herceptin)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
Generate the TRASTUZUMAB (Herceptin) PA packet
Open ApprovalHelp — generate a TRASTUZUMAB (Herceptin) prior-auth packet tailored to Regence's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com